New combo therapy targets advanced sarcoma in early trial
NCT ID NCT07205185
First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This study tests a new drug combination for people with advanced soft tissue sarcoma that has not responded to earlier treatments. The treatment includes an immunotherapy drug (epalrotokewali) plus chemotherapy, a targeted therapy, and radiation. The goal is to see if this combination can shrink or control tumors. About 46 participants aged 14 to 75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA (STS) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.